Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03938545 · ClinicalTrials.gov registry record · Phase 2
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
A Phase 2 study, sponsored by Immunovant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT03938545 is a Phase 2 study that was terminated before completion, run by Immunovant Sciences. The registered enrollment target is 65 participants.
The verdict
NCT03938545, a Phase 2 study, was terminated before completion, sponsored by Immunovant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG
Interventions
- DRUG RVT-1401 (Administered via subcutaneous injection)
- OTHER Placebo (Administered via subcutaneous injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2021-04-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03938545
The ClinicalTrials.gov registry entry for NCT03938545 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunovant Sciences, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RVT-1401 (Administered via subcutaneous injection) is the first listed.
NCT03938545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03938545 about?
NCT03938545 is a clinical study titled "ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )". The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG
What is the current status of trial NCT03938545?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2019-07-23. Estimated completion is 2021-04-15.
What interventions are being tested in trial NCT03938545?
The interventions under investigation include: RVT-1401 (Administered via subcutaneous injection) (DRUG), Placebo (Administered via subcutaneous injection) (OTHER).
Who is sponsoring clinical trial NCT03938545?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.